1 Min Read
Nov 15 (Reuters) - IRLAB THERAPEUTICS AB:
* IRLAB RECEIVES MHRA APPROVAL TO CONDUCT PHASE II TRIALS WITH IRL790 IN BRITAIN Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.